Figure 2
The clinical outcome of gastric cancer patients who received nivolumab monotherapy in the overall population, and its association with tissue-based biomarkers including dMMR and PD-L1 CPS. Kaplan–Meier estimates of progression-free survival (PFS, a) and overall survival (OS, b) of overall gastric cancer patients treated with nivolumab monotherapy. Disease control rate (DCR, c), and Kaplan–Meier estimates of PFS (d), as well as OS (e), according to dMMR status. Disease control rate (DCR, f), and Kaplan–Meier estimates of PSF (g), as well as OS (h), of patients stratified by PD-L1 CPS of 1. dMMR mismatch repair-deficient, MSI-H microsatellite instability-high, MSS microsatellite stable, PD-L1 CPS programmed death ligand 1 combined positive score, PR partial response, SD stable disease.
